+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Cardio-Protective Drug Market Research and Forecast 2018-2023

  • ID: 4700804
  • Report
  • October 2018
  • Region: Global
  • Orion Market Research Private Limited
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now


  • Amgen Inc.
  • Bayer Ag
  • Daiichi Sankyo Co Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • Merck & Co. Inc.
  • MORE
Cardio-protective drug mainly involves in the prevention of heart and blood vessel blockage which leads to heart attack, chest pain or other heart problems. Cardio-protection drugs are mainly used before an ischemic event, during an ischemic event and after the event and during reperfusion. These drugs are important in the treatment of patients at risk for or with a documented cardiovascular disease. Beta-blockers are indicated after acute coronary syndromes, stable coronary artery disease, heart failure, and arrhythmias. Global Cardioprotective drug market is expected to witness a significant growth during the forecast period.

Factors motivating the growth of this market include increasing geriatric population and an increase in excessive alcohol consumption & smoking. Other factors that are driving the growth of the market includes increasing prevalence of chronic heart diseases and technological advancement in healthcare industry. High cost of medication and diagnostics procedure of heart disease are the major restraining factors restraining to the growth of this market. However, advancement in pharmaceutical biotechnology for drug development have fuelled the growth of this market. Growing healthcare expenditure in emerging economies and increase in R&D activities by pharmaceutical companies for drug discovery is expected to drive the growth of the market in near future.

Cardioprotective drug market is geographically divided into North America, Europe, Asia Pacific and Rest of the World. In terms of its uses and revenue generation North America region represents considerably a largest market for cardio-protective drugs. Advancement in pharmaceutical biotechnology in the US for drug development and increase in number of cardiovascular patients are the major driving factor in North America region. Developing nations that are experiencing impressive growth in their economy over the past few years such as India, China, Brazil, Mexico and South Africa have a great potential for cardioprotective drug market. Increasing government funding to improve healthcare infrastructure and increase in geriatric population are the major factor which drives this market in the APAC region. Europe is expected to have a lucrative growth in this market. This is due to the subsequent rise in the incidence of cardiovascular diseases such as stroke, heart failure, hypertensive heart disease, rheumatic heart disease and so on. The major countries that will contribute to the market are the UK, Germany, Spain, France, Italy.

The global players in the Cardio-protective drug market include Amgen, Bayer AG, Bristol-Myers Squibb company, Sanofi, F. Hoffmann-La Roche Ltd, Mayo clinics. The strategy adopted by these companies are continuous investments in (R&D) which made them progress over the past several years in the market. other strategies adopted by the market player include merger & acquisition, collaboration & partnership, product launch and so on. For instance, in January 2018, Sanofi acquired Ablynx to expand their product portfolio for rare blood disorders and continue to advance the strategic transformation for drug discovery.

Research methodology

The market study of global cardioprotective drug market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary sources include
  • Financial reports of companies involved in the market
  • Authentic Public Databases such as the FDA, WHO and others
  • Whitepapers, research-papers and news blogs
  • Company websites and their product catalog.
The Report is intended for cardioprotective drug manufacturers, cardio-protective drug API manufacturer, Investing companies, Government Organizations for overall market analysis and competitive analysis. The report provides in-depth analysis of pricing, market size, intended quality of the product preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating with delivering insights into the market for better business decisions.

Market segmentation

The Global Cardioprotective Drug market is segmented on the basis of regional outlook and following segments:
  • Global Cardioprotective drug market Research and Analysis, By treatment
  • Global Cardioprotective drug market Research and Analysis, By type
  • Global Cardioprotective drug market Research and Analysis, By application
  • Global Cardioprotective drug market Research and Analysis, By distribution channels
The Report Covers:
  • Comprehensive research methodology of the global cardioprotective drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global cardio-protective drug market.
  • Insights about market determinants which are stimulating the Global Cardioprotective drug market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3


  • Amgen Inc.
  • Bayer Ag
  • Daiichi Sankyo Co Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • Merck & Co. Inc.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders

2. Market Overview and Insights
2.1. Definition
2.2. Analyst Insights & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendation
2.2.3. Conclusion
2.3. Regulation United States European Union China India

3. Market Determinant
3.1. Motivators
3.1.1. Increasing Geriatric Population.
3.1.2. Increasing Prevalence of Chronic Heart Diseases
3.1.3. Increase in Excessive Alcohol Consumption & Smoking.
3.1.4. Technological Advancement in Healthcare.
3.2. Restraint
3.2.1. High Medication Cost.
3.2.2. Strict Governmental Regulation for Drug Approval.
3.3. Opportunity
3.3.1. Increase in R&D Activities By Pharmaceutical Companies for Drug Discovery.
3.3.2. Increasing Healthcare Expenditure in Developing Nation.

4. Market Segmentation
4.1. Global Cardio-Protective Drugs Market, By Treatment
4.1.1. Cholesterol Lowering
4.1.2. Revascularization
4.1.3. Anti-Inflammatory
4.1.4. Blood Thinners & Clot Busters
4.2. Global Cardio-Protective Drugs Market, By Type
4.2.1. Antiplatelets
4.2.2. Ace Inhibitors & Arbs
4.2.3. Beta-Blockers
4.2.4. Polypills
4.2.5. Statins & Others
4.3. Global Cardio-Protective Drugs Market, By Application
4.3.1. Arrhythmia
4.3.2. Coronary Artery Disease
4.3.3. Ischemic Heart Disease
4.3.4. Cardiovascular Disease
4.3.5. Hyperlipidaemia
4.3.6. Peripheral Heart Disease
4.3.7. Hypertension
4.4. Global Cardio-Protective Drugs Market, By Distribution Channel
4.4.1. Hospital Pharmacy
4.4.2. Online Pharmacy
4.4.3. Retail Pharmacy

5. Competitive Landscape
5.1. Key Strategies
5.2. Key Company Analysis

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. Uk
6.2.2. Germany
6.2.3. Spain
6.2.4. France
6.2.5. Italy
6.2.6. Rest of Europe
6.3. Asia Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.3.4. Rest of APAC
6.4. Rest of The World

7. Company Profiles
7.1. Astrazeneca Plc
7.2. Amgen Inc.
7.3. Bayer Ag
7.4. Boehringer Ingelheim Gmbh
7.5. Bristol-Myers Squibb Company
7.6. Daiichi Sankyo Co Ltd.
7.7. Eli Lilly and Company
7.8. F. Hoffmann-La Roche Ltd.
7.9. Glaxosmithkline Plc
7.10. Gilead Sciences, Inc.
7.11. Johnson & Johnson
7.12. Merck & Co. Inc.
7.13. Novartis Ag
7.14. Nissan Chemical Corporation
7.15. Otsuka Holdings Co., Ltd.
7.16. Pfizer Inc.
7.17. Sanofi S.A.
7.18. Siemens Healthineer
7.19. Takeda Pharmaceuticals Company Ltd.
7.20. Tenax Therapeutics Inc
Note: Product cover images may vary from those shown
3 of 3
  • Astrazeneca Plc
  • Amgen Inc.
  • Bayer Ag
  • Boehringer Ingelheim Gmbh
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co Ltd.
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis Ag
  • Nissan Chemical Corporation
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Siemens Healthineers
  • Takeda Pharmaceuticals Company Ltd.
  • Tenax Therapeutics Inc
Note: Product cover images may vary from those shown